Lamisil At (Terbinafine)

Terbinafine acts by inhibiting the fungal enzyme squalene epoxidase, which is essential for ergosterol synthesis in the cell membrane. Blocking this step leads to toxic accumulation of squalene and depletion of ergosterol, compromising membrane integrity and causing fungal cell death while sparing human cells that use a different cholesterol pathway.

The amount of Lamisil At to apply is determined by the prescribing healthcare professional based on the infection’s location, severity, patient age and skin condition. Patients should follow the specific instructions provided by their clinician and the product label, as dosing is not standardized across all cases.

Safety data for topical terbinafine in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil At. The prescriber will decide whether the treatment is appropriate.

To order Lamisil At, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lamisil At (terbinafine) belongs to the allylamine class, which differs from azole antifungals such as clotrimazole or miconazole. Allylamines target squalene epoxidase, offering a rapid fungicidal effect and often requiring shorter treatment durations. In contrast, azoles inhibit lanosterol 14‑α‑demethylase and may be more suitable for certain yeast infections. Choice of therapy depends on the pathogen, infection site and clinician preference.

Lamisil At should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture, direct sunlight and excessive heat. Do not freeze the product. Handling should be performed with clean hands, and any unused portion should be discarded after the expiration date.

Before application, wash and thoroughly dry the affected skin area. Apply a thin layer of Lamisil At to the lesion and the surrounding skin, usually once or twice daily as directed by the prescriber. Gently rub the cream or gel into the skin until it disappears, and wash hands after use to avoid accidental contact with eyes or mucous membranes.

While most reactions are mild, serious risks include severe allergic responses such as swelling, hives, or difficulty breathing, and rare but life‑threatening skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. In very uncommon cases, systemic absorption may lead to liver enzyme abnormalities. Users should seek immediate medical attention if they experience any signs of a severe reaction.

Lamisil At should be avoided by individuals with known hypersensitivity to terbinafine, other allylamines, or any component of the formulation. It is also contraindicated in patients who have experienced severe cutaneous adverse reactions to topical antifungals. Children under the age specified on the product label should not use the medication unless directed by a qualified healthcare professional.